Bayer’s Dual Narrative: A Crop Science Endorsement Meets a Pharma Pipeline Rebuttal

The investment case for Bayer is increasingly being written on two separate pages. While Wall Street’s attention has gravitated toward the agricultural arm, fresh clinical data from the pharmaceuticals division is quietly reshaping the bull thesis — and giving shareholders a second pillar to lean on as the company’s legal overhang lingers.

JPMorgan has reaffirmed its “Overweight” rating on the stock, with analysts singling out the Crop Science unit as an underappreciated asset that has recently gathered momentum. The endorsement aligns with a broader consensus that remains constructive: the majority of covering houses carry “Buy” or “Strong Buy” ratings, with only scattered “Hold” recommendations breaking the pattern. That positioning was reinforced by the latest quarterly figures, which came in ahead of expectations on both earnings per share and revenue, alongside a full-year EPS guidance range that offers a benchmark for the quarters ahead.

Yet the more compelling development may be unfolding in the pharma segment, where Bayer has unveiled study results for finerenone, marketed as Kerendia. The data demonstrated that the drug slowed kidney function decline in patients with hypertensive nephropathy and reduced combined renal and cardiovascular risks. For investors, the significance extends beyond the clinical realm — Kerendia, alongside the oncology drug Nubeqa, represents one of the two growth pillars in a pharma division that has otherwise struggled operationally.

The numbers illustrate the urgency. In the second quarter of 2026, Nubeqa and Kerendia posted combined growth of 66 percent, even as overall pharma revenue contracted by 3.6 percent. The drag comes largely from Eylea, once the franchise’s cornerstone, which saw sales fall 27 percent amid biosimilar competition. Bayer is counting on Kerendia’s expanded indication — moving beyond diabetic kidney disease into hypertensive nephropathy, a condition affecting millions worldwide — to help fill that widening gap. Regulatory approval for the broader use case would substantially enlarge the drug’s addressable market.

Should investors sell immediately? Or is it worth buying Bayer?

The pipeline story gains further depth from Asundexian, which has secured accelerated review status in both the US and China, with a potential market launch targeted for late 2026 or early 2027. Together with Kerendia’s momentum, these assets are positioned to offset Eylea’s decline over the medium term — a crucial counterweight as the pharma division seeks to prove it is more than a repair job.

The market’s response to this improving news flow has been measured but positive. The shares closed Thursday at €49.54, leaving the stock up 34 percent since the start of the year. The current price sits 1.9 percent above the 50-day moving average of €48.63, suggesting the near-term uptrend remains intact, though the stock still trades 8.0 percent below its 52-week high of €53.86 reached in July.

Friday’s session brought a modest pullback, with shares easing to €48.99 after the previous day’s close. The dip appears more a function of broader market jitters than company-specific concerns — investors are awaiting the US jobs report, and soft private payroll data released a day earlier had already injected a note of caution into trading. Such conditions can pressure European blue chips regardless of their underlying fundamentals.

The legal calendar remains the wildcard that no amount of operational progress can fully neutralize. The hearing for final approval of the Roundup settlement has been rescheduled to September 14, roughly a month from now, keeping the litigation overhang firmly in view. Until that matter resolves, the shares will likely carry a discount that reflects legal uncertainty rather than commercial performance — a dynamic that leaves Bayer’s story bifurcated between what the business is achieving and what the courts have yet to decide.